On the upside
Bargain hunters continued to lift shares of Peregrine Pharmaceuticals (Nasdaq: PPHM), whose stock price plunged on Monday after revealing discrepancies in a drug trial.
A judged ruled in favor of Life Partners Holdings (Nasdaq: LPHI) in a suit filed by Texas Attorney General Greg Abbott that the company deceived buyers of interests in life insurance policy settlements.
On the downside
Catalyst Pharmaceutical Partners (Nasdaq: CPRX) announced that results from a Phase II(b) clinical trial of its cocaine addiction treatment CPP-109 will be delayed.
Jabil Circuit (NYSE: JBL) disappointed with lower fourth quarter earnings that fell short of analyst expectations and forecast current quarter results below estimates.
Fortinet (Nasdaq: FTNT) chief financial officer Ken Goldman will join Yahoo (Nasdaq: YHOO) as its new chief financial officer on October 22.
In the broad market, declining issues outpaced advancers by a margin of 7 to 5 on the NYSE and by 9 to 7 on Nasdaq. The Russell 2000 which tracks small cap stocks slipped a point to 837.